Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Core Points - Apollomics Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, with a new deadline set for January 13, 2025 [1][2] - The company had previously been notified on January 16, 2024, that it was not in compliance due to its Ordinary Shares closing bid price being below$1.00 for 30 consecutive business days [1][2] - If the closing bid price reaches at least $1.00 for ten consecutive business days before the deadline, Nasdaq will confirm compliance [2] - The company is actively monitoring its share prices and evaluating options to regain compliance, but there is no assurance of success [3] Company Overview - Apollomics Inc. is a late-stage clinical biopharmaceutical company focused on developing oncology therapies for difficult-to-treat and treatment-resistant cancers [1][4] - The company's lead product, vebreltinib (APL-101), is a selective c-Met inhibitor currently in a Phase 2 clinical trial for non-small cell lung cancer and other advanced tumors [4] - Another key product, uproleselan (APL-106), is an E-Selectin antagonist in Phase 1 and Phase 3 trials for acute myeloid leukemia and other hematologic cancers [4]